Legal & General Group Plc raised its stake in shares of Five Prime Therapeutics, Inc. (NASDAQ:FPRX) by 39.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,168 shares of the biotechnology company’s stock after buying an additional 2,583 shares during the period. Legal & General Group Plc’s holdings in Five Prime Therapeutics were worth $331,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the stock. Norges Bank acquired a new position in shares of Five Prime Therapeutics during the fourth quarter valued at $7,080,000. UBS Asset Management Americas Inc. raised its position in shares of Five Prime Therapeutics by 481.1% in the fourth quarter. UBS Asset Management Americas Inc. now owns 156,301 shares of the biotechnology company’s stock valued at $7,833,000 after buying an additional 129,404 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Five Prime Therapeutics by 0.7% in the fourth quarter. Teachers Advisors LLC now owns 238,428 shares of the biotechnology company’s stock valued at $11,948,000 after buying an additional 1,558 shares in the last quarter. Creative Planning raised its position in shares of Five Prime Therapeutics by 42.6% in the first quarter. Creative Planning now owns 6,690 shares of the biotechnology company’s stock valued at $242,000 after buying an additional 2,000 shares in the last quarter. Finally, Nationwide Fund Advisors raised its position in shares of Five Prime Therapeutics by 3.1% in the first quarter. Nationwide Fund Advisors now owns 59,400 shares of the biotechnology company’s stock valued at $2,147,000 after buying an additional 1,771 shares in the last quarter. Hedge funds and other institutional investors own 85.10% of the company’s stock.

Five Prime Therapeutics, Inc. (FPRX) opened at 29.79 on Tuesday. The stock’s 50 day moving average price is $29.82 and its 200 day moving average price is $35.52. Five Prime Therapeutics, Inc. has a one year low of $26.65 and a one year high of $60.98. The firm’s market capitalization is $831.05 million.

COPYRIGHT VIOLATION WARNING: “Five Prime Therapeutics, Inc. (FPRX) Position Boosted by Legal & General Group Plc” was published by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/08/five-prime-therapeutics-inc-fprx-position-boosted-by-legal-general-group-plc.html.

FPRX has been the subject of several recent analyst reports. Zacks Investment Research upgraded Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a research note on Wednesday, April 26th. Jefferies Group LLC reiterated a “buy” rating and issued a $55.00 price objective on shares of Five Prime Therapeutics in a report on Friday, May 5th. ValuEngine upgraded Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, June 2nd. Finally, BidaskClub cut Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Wednesday, August 2nd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company’s stock. Five Prime Therapeutics presently has an average rating of “Buy” and an average price target of $60.83.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics, Inc. (NASDAQ:FPRX).

Institutional Ownership by Quarter for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.